FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008646009> ?p ?o ?g. }

• W2008646009 endingPage "45" @default.
• W2008646009 startingPage "37" @default.
• W2008646009 abstract "Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)-ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks. A 24-week course of SOF/RBV costs approximately US$169,000, with sustained virologic response (SVR) rates ranging from 52% to 84%; 12 weeks of SOF/SMV costs approximately $150,000, with SVR between 89% and 100%. Because SOF/SMV is currently used off-label, debate exists among physicians and payers about whether it should be prescribed and covered. This article presents a cost-effectiveness analysis of these two treatment regimens accounting for costs of drugs, treatment-related medical care, retreatment for individuals who do not achieve SVR, and natural history of continued HCV infection after failed retreatment. Analysis uses a Markov model with a lifetime horizon and a societal perspective. In the base-case scenario, SOF/SMV dominated SOF/RBV in a modeled 50-year-old cohort of treatment-naïve and -experienced subjects, excluding those who failed earlier therapy with telaprevir or boceprevir. SOF/SMV yielded lower costs and more quality-adjusted life years (QALYs) for the average subject, compared to SOF/RBV ($165,336 and 14.69 QALYs vs. $243,586 and 14.45 QALYs, respectively). In base-case cost analysis, the SOF/SMV treatment strategy saved $91,590 per SVR, compared to SOF/RBV. Under all one-way sensitivity scenarios, SOF/SMV remained dominant and resulted in cost savings. Conclusions: These results suggest that a 12-week course of SOF/SMV is a more cost-effective treatment for genotype 1 CHC than 24 weeks of SOF/RBV among IFN-ineligible/intolerant individuals, supporting the AASLD/IDSA guidance and offering implications for both clinical and regulatory decision making as well as pharmaceutical pricing. (Hepatology 2014;60:37–45)" @default.
• W2008646009 created "2016-06-24" @default.
• W2008646009 creator A5018141606 @default.
• W2008646009 creator A5054201295 @default.
• W2008646009 creator A5087052821 @default.
• W2008646009 date "2014-05-14" @default.
• W2008646009 modified "2023-09-27" @default.
• W2008646009 title "Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals" @default.
• W2008646009 cites W1789913733 @default.
• W2008646009 cites W1965824583 @default.
• W2008646009 cites W1967982404 @default.
• W2008646009 cites W1971999670 @default.
• W2008646009 cites W1983818291 @default.
• W2008646009 cites W1984413237 @default.
• W2008646009 cites W1991395575 @default.
• W2008646009 cites W1992690275 @default.
• W2008646009 cites W1998686118 @default.
• W2008646009 cites W1999585106 @default.
• W2008646009 cites W2002345728 @default.
• W2008646009 cites W2003307697 @default.
• W2008646009 cites W2012873820 @default.
• W2008646009 cites W2015763165 @default.
• W2008646009 cites W2016429992 @default.
• W2008646009 cites W2021207134 @default.
• W2008646009 cites W2022967348 @default.
• W2008646009 cites W2031280279 @default.
• W2008646009 cites W2033555988 @default.
• W2008646009 cites W2044448697 @default.
• W2008646009 cites W2058200448 @default.
• W2008646009 cites W2077550422 @default.
• W2008646009 cites W2085684927 @default.
• W2008646009 cites W2091863240 @default.
• W2008646009 cites W2094174828 @default.
• W2008646009 cites W2106485849 @default.
• W2008646009 cites W2111044696 @default.
• W2008646009 cites W2118181377 @default.
• W2008646009 cites W2127497497 @default.
• W2008646009 cites W2141769755 @default.
• W2008646009 cites W2143456878 @default.
• W2008646009 cites W2148840656 @default.
• W2008646009 cites W2148913966 @default.
• W2008646009 cites W2152870084 @default.
• W2008646009 cites W2164439784 @default.
• W2008646009 cites W2164668044 @default.
• W2008646009 cites W3021771012 @default.
• W2008646009 doi "https://doi.org/10.1002/hep.27151" @default.
• W2008646009 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4077973" @default.
• W2008646009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24677184" @default.
• W2008646009 hasPublicationYear "2014" @default.
• W2008646009 type Work @default.
• W2008646009 sameAs 2008646009 @default.
• W2008646009 citedByCount "101" @default.
• W2008646009 countsByYear W20086460092014 @default.
• W2008646009 countsByYear W20086460092015 @default.
• W2008646009 countsByYear W20086460092016 @default.
• W2008646009 countsByYear W20086460092017 @default.
• W2008646009 countsByYear W20086460092018 @default.
• W2008646009 countsByYear W20086460092019 @default.
• W2008646009 countsByYear W20086460092020 @default.
• W2008646009 countsByYear W20086460092021 @default.
• W2008646009 countsByYear W20086460092022 @default.
• W2008646009 crossrefType "journal-article" @default.
• W2008646009 hasAuthorship W2008646009A5018141606 @default.
• W2008646009 hasAuthorship W2008646009A5054201295 @default.
• W2008646009 hasAuthorship W2008646009A5087052821 @default.
• W2008646009 hasBestOaLocation W20086460091 @default.
• W2008646009 hasConcept C126322002 @default.
• W2008646009 hasConcept C159047783 @default.
• W2008646009 hasConcept C2522874641 @default.
• W2008646009 hasConcept C2776408679 @default.
• W2008646009 hasConcept C2776455275 @default.
• W2008646009 hasConcept C2777159539 @default.
• W2008646009 hasConcept C2778159067 @default.
• W2008646009 hasConcept C2778390639 @default.
• W2008646009 hasConcept C2778986448 @default.
• W2008646009 hasConcept C2780040827 @default.
• W2008646009 hasConcept C71924100 @default.
• W2008646009 hasConceptScore W2008646009C126322002 @default.
• W2008646009 hasConceptScore W2008646009C159047783 @default.
• W2008646009 hasConceptScore W2008646009C2522874641 @default.
• W2008646009 hasConceptScore W2008646009C2776408679 @default.
• W2008646009 hasConceptScore W2008646009C2776455275 @default.
• W2008646009 hasConceptScore W2008646009C2777159539 @default.
• W2008646009 hasConceptScore W2008646009C2778159067 @default.
• W2008646009 hasConceptScore W2008646009C2778390639 @default.
• W2008646009 hasConceptScore W2008646009C2778986448 @default.
• W2008646009 hasConceptScore W2008646009C2780040827 @default.
• W2008646009 hasConceptScore W2008646009C71924100 @default.
• W2008646009 hasFunder F4320306127 @default.
• W2008646009 hasFunder F4320332161 @default.
• W2008646009 hasIssue "1" @default.
• W2008646009 hasLocation W20086460091 @default.
• W2008646009 hasLocation W20086460092 @default.
• W2008646009 hasLocation W20086460093 @default.
• W2008646009 hasLocation W20086460094 @default.
• W2008646009 hasOpenAccess W2008646009 @default.
• W2008646009 hasPrimaryLocation W20086460091 @default.
• W2008646009 hasRelatedWork W1975576681 @default.

• next